BRPI0809890A2 - Processo para preparar imatinib ou sal do mesmo e composição farmacêutica - Google Patents

Processo para preparar imatinib ou sal do mesmo e composição farmacêutica

Info

Publication number
BRPI0809890A2
BRPI0809890A2 BRPI0809890-5A2A BRPI0809890A BRPI0809890A2 BR PI0809890 A2 BRPI0809890 A2 BR PI0809890A2 BR PI0809890 A BRPI0809890 A BR PI0809890A BR PI0809890 A2 BRPI0809890 A2 BR PI0809890A2
Authority
BR
Brazil
Prior art keywords
salt
pharmaceutical composition
preparing imatinib
imatinib
preparing
Prior art date
Application number
BRPI0809890-5A2A
Other languages
English (en)
Inventor
Liu Xing
He Xungui
Yuan Wang
Michel Bekhazi
Sonia Krivonos
Edna Danon
Original Assignee
Chemagis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemagis Ltd filed Critical Chemagis Ltd
Publication of BRPI0809890A2 publication Critical patent/BRPI0809890A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0809890-5A2A 2007-05-02 2008-05-01 Processo para preparar imatinib ou sal do mesmo e composição farmacêutica BRPI0809890A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/743,520 US7550591B2 (en) 2007-05-02 2007-05-02 Imatinib production process
PCT/IL2008/000591 WO2008135980A1 (en) 2007-05-02 2008-05-01 Imatinib production process

Publications (1)

Publication Number Publication Date
BRPI0809890A2 true BRPI0809890A2 (pt) 2014-09-30

Family

ID=39744792

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809890-5A2A BRPI0809890A2 (pt) 2007-05-02 2008-05-01 Processo para preparar imatinib ou sal do mesmo e composição farmacêutica

Country Status (5)

Country Link
US (1) US7550591B2 (pt)
EP (1) EP2146978A1 (pt)
JP (1) JP2010526056A (pt)
BR (1) BRPI0809890A2 (pt)
WO (1) WO2008135980A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
KR20090061068A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 이매티닙의 제조 방법
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
WO2009080366A1 (en) * 2007-12-22 2009-07-02 Synthon B.V. A process of making imatinib
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2011095835A1 (en) * 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
KR20130055576A (ko) * 2010-03-15 2013-05-28 낫코 파마 리미티드 고순도의 결정질 이마티닙 염기를 제조하는 방법
CN103864752B (zh) * 2010-05-19 2015-11-25 江苏豪森药业股份有限公司 甲磺酸伊马替尼的晶型及其制备方法
CN101985442B (zh) * 2010-09-19 2013-04-03 南京卡文迪许生物工程技术有限公司 一种便捷的制备高纯度的伊马替尼及其甲磺酸盐的方法
CN102070605B (zh) * 2011-01-30 2013-03-13 南京卡文迪许生物工程技术有限公司 甲磺酸伊马替尼多晶型物和药用组合物
KR101286780B1 (ko) 2011-02-01 2013-07-17 에스티팜 주식회사 비카보네이트 염 및 이를 이용한 이마티니브 또는 이의 염의 제조방법
JP2014509642A (ja) 2011-03-31 2014-04-21 アイエヌディー−スイフト ラボラトリーズ リミテッド イマチニブ及びそのメシル酸塩の生成のための改良方法
CN102796079B (zh) * 2011-05-27 2016-06-29 江苏豪森药业集团有限公司 一种甲磺酸氟马替尼的制备方法
CN102260242B (zh) * 2011-05-27 2014-08-06 南京卡文迪许生物工程技术有限公司 甲磺酸伊马替尼多晶型物及其药用组合物
KR101139431B1 (ko) * 2011-05-30 2012-04-27 (주)비씨월드제약 이매티닙 염기의 신규한 제조방법
CN102816145B (zh) * 2011-06-11 2014-09-03 南京卡文迪许生物工程技术有限公司 甲磺酸伊马替尼多晶型物及其药用组合物
WO2013120852A1 (en) * 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
WO2013136141A1 (en) 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
CN102659762A (zh) * 2012-05-24 2012-09-12 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼晶型及其制备方法
CN104974133B (zh) * 2014-04-09 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼晶型及其制备方法
CN105859683B (zh) * 2016-04-11 2018-09-28 连云港恒运药业有限公司 伊马替尼的高纯度工业制备工艺
CN112359079B (zh) * 2020-11-10 2022-07-26 江苏八巨药业有限公司 一种伊马胺的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2003073352A (ja) * 2001-09-05 2003-03-12 Sumitomo Pharmaceut Co Ltd 新規な環状アミン化合物
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
TR200504337T1 (tr) 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
AR047530A1 (es) 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
US8269003B2 (en) 2004-09-02 2012-09-18 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
EP2266579A1 (en) * 2004-10-19 2010-12-29 Achillion Pharmaceuticals, Inc. Pharmaceutical composition comprising elvucitavine
WO2006054314A1 (en) 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US7507821B2 (en) * 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
AU2006283842B2 (en) 2005-08-26 2011-03-17 Novartis Ag Delta and epsilon crystal forms of imatinib mesylate
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
CA2680249A1 (en) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories, Inc. Imatinib mesylate

Also Published As

Publication number Publication date
JP2010526056A (ja) 2010-07-29
US7550591B2 (en) 2009-06-23
WO2008135980A1 (en) 2008-11-13
US20080275055A1 (en) 2008-11-06
EP2146978A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
BRPI0809890A2 (pt) Processo para preparar imatinib ou sal do mesmo e composição farmacêutica
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
BRPI0913707A2 (pt) "artigo e métodos para preparação do artigo"
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0816513A2 (pt) Composição farmacêutica e método para preparar a suspensão sólida
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0810763A2 (pt) Composição aglutinante betuminosa e processo para preparação da mesma
BR112012002628A2 (pt) "composição para tratamento de infecções por hbv"
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0911681A2 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
FR2912751B1 (fr) Procede de preparation de polylactones et polylactames
BRPI0905847A2 (pt) "composição farmacêutica injetável e processo para preparar a composição"
BRPI0915594A2 (pt) composição fungicida e processo para o controle de doenças de plantas
BRPI0910545A2 (pt) processo contínuo para fazer composições farmacêuticas
BRPI1008727A2 (pt) derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
BRPI0916381A2 (pt) métodos e sistemas para preparação de materiais para produção de sucralose
BRPI0811930A2 (pt) Métodos e composições para a identificação e o tratamento de lúpus
BRPI0910785A2 (pt) sal de eritromicina hidratado, composição farmacêutica, processo para preparar um sal de eritromicina hidratado e uso de sal de eritromicina hidratado
BRPI0816519A2 (pt) Processo para preparar um sal de r, r'-atracúrio isomericamente enriquecido e sal de r, r'-atracúrio
BRPI0812359A2 (pt) Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
BRPI0820413A2 (pt) Polinucleotídeos e métodos para o melhoramento de plantas
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.